Skip to content

The Potential of Transcutaneous Electrical Nerve Stimulation to Improve Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome

The Value of Transcutaneous Electrical Nerve Stimulation (TENS) for Improving Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome: a Single-center, Randomized, Double-blind, Parallel-group, Controlled, Superiority Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07627490
Acronym
TENS-INFIDOL
Enrollment
52
Registered
2026-06-04
Start date
2026-09-01
Completion date
2028-09-01
Last updated
2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Back Pain Chronic

Keywords

chronic lower back pain, pain, transcutaneous electrical neurostimulation

Brief summary

Procedural pain is inadequately managed in two-thirds of patients undergoing invasive medical procedures. Several techniques exist for managing procedural pain, but they all present implementation challenges and are not without side effects. Therefore, a new, non-pharmacological, inexpensive, and easy-to-use approach would be of significant benefit. Transcutaneous electrical nerve stimulation (TENS) for pain relief could represent this alternative. Few studies have been conducted on the benefits of TENS in managing procedural pain, for example, in shoulder arthrodistension. This project proposes to study it in the context of posterior ramus infiltration in patients eligible for this indication, in the context of chronic low back pain associated with posterior joint syndrome.

Interventions

PROCEDUREStimulation with TENS, which allows the release of endorphins

Stimulation with TENS at frequencies that allow the release of endorphins before infiltration

PROCEDUREStimulation with TENS does not allow the release of endorphins

Stimulation with TENS at levels that do not allow the release of endorphins prior to infiltration

OTHERQuestionnaires

Pain questionnaires will need to be completed at the inclusion, one month and 3 months

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic low back pain (lasting more than 3 months) * Patient followed in a Chronic Pain Unit (CETD, Toulouse University Hospital) * Clinical and radiological diagnosis (CT scan or MRI) of posterior joint syndrome * Patient with an indication for infiltration therapy, feasible under standard conditions

Exclusion criteria

* Spinal surgery * Contraindications for TENS: * Wearing an electronic medical device (pacemakers, defibrillators, etc.) * Pregnancy * Area of cutaneous anesthesia * Patient with an active malignant tumor * Patient with deep vein thrombosis * Patient with damaged or fragile skin * Insulin-dependent or uncontrolled diabetes * Uncontrolled hypertension * Allergy to the local anesthetics used * Severe psychiatric disorder * Lumbar injection within the previous 6 months

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the intensity of pain experienced during the infiltration procedure between the intervention group and the placebo group3 months after the inclusionPain assessment using the visual analog scale

Secondary

MeasureTime frameDescription
Evaluation of satisfaction with the infiltration procedure in both groups3 months after the inclusionSatisfaction questionnaire to be completed regarding the infiltration procedure
Comparison of the effectiveness of posterior branch block on pain in both groups3 months after the inclusionPain questionnaires to be completed
Assessment of pain experienced by the patient in the 2 groups3 months after the inclusionQuestionnaire on the reduction of perceived pain

Countries

France

Contacts

CONTACTMarc LABROUSSE, MD
labrousse.m@chu-toulouse.Fr06 21 41 75 03

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 5, 2026